Company intelligence / Profile preview

Hubro Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Hubro Therapeutics develops proprietary therapeutic and prophylactic peptide vaccines targeting tumor-specific neoantigens resulting from microsatellite instability and frameshift mutations. Its lead program, FMPV‑1, targets TGFBR2 frameshift mutations in colorectal cancer and has reached Phase 2. The next-generation candidate FMPV‑3 targets multiple shared neoantigens for hereditary MSI cancers and was preclinical as of early/mid‑2025. No published clinical efficacy data yet.

Therapeutic areas: Oncology
Modalities: Therapeutic vaccineSynthetic peptide vaccineRecombinant polypeptide
Industry: Biotech

Drug pipeline

1 asset

FMPV-1

Partnerships

Targovax (acquisition of a proprietary adjuvant for use in vaccines)

Beyond the preview

Go deeper on Hubro Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hubro Therapeutics.

Explore the full profile